NCT02472938撤回4 期
Phase IV, Interventional, multicenteR, Double-blind, Randomized, Placebo-controlled Study tO Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With relapsingremitTing Multiple Sclerosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- Biogen
- 主要终点
- Mean number of cumulative combined unique active (CUA) lesions (registered from week 4 to 24)
研究概览
简要总结
The primary objective of the study is to assess the early efficacy of treatment with BG00012 (dimethyl fumarate) 240 mg twice daily (BID) in the brain of newly diagnosed and naive-to-treatment patients with relapsing-remitting multiple sclerosis (RRMS). The Secondary objectives are to establish the time course of the beneficial effect of BG00012 240 mg BID over 24 weeks and to evaluate the safety of BG00012.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with RRMS (McDonald criteria, 2010) who do not accept current injectable firstline DMTs.
- •Multiple sclerosis (MS) onset within one year before enrolment
- •≥ 1 Gd+ lesions at a brain MRI scan performed within three months beforeenrolment.
- •No previous disease modifying and/or immunosuppressive treatments for MS.
- •Must have a baseline EDSS between 0.0 and 5.0, inclusive. · Women of childbearing potential (i.e. who are not post-menopausal for at least 1 year) and men must practice effective contraception (as defined by the Investigator) during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.
排除标准
- •Primary progressive, secondary progressive, or progressive relapsing MS, as defined by Lublin and Reingold (Lublin and Reingold 1996)
- •Previous disease modifying and/or immunosuppressive treatments for MS, including Tcell or T-cell receptor vaccination, any therapeutic monoclonal antibody, Mitoxantrone, Cyclophosphamide
- •Previous treatment with Fumaderm®, dimethyl fumarate or other fumarates
- •History of malignancy (except basal cell carcinoma that has been completely excised prior to study enrollment)
- •History of severe allergic or anaphylactic reactions or known drug hypersensitivity.Known allergy/hypersensitivity to Gadolinium.
- •History of abnormal laboratory results indicative of any significant endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, renal, and/or other major disease that in the opinion of the Investigator would preclude participation in a clinical trial.
- •History of or positive test result at screening for human immunodeficiency virus (HIV).Positive for hepatitis C antibody and/or positive for hepatitis B surface antigen (HBsAg) at screening.
- •History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to inclusion.
- •An MS relapse that has occurred within the 30 days prior to inclusion (screening) AND/OR the subject has not stabilized from a previous relapse prior to inclusion.
- •NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
研究组 & 干预措施
BG00012
Experimental
120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
干预措施: dimethyl fumarate (Drug)
Placebo
Placebo Comparator
Placebo capsules orally twice a day.
干预措施: Placebo (Other)
结局指标
主要结局
Mean number of cumulative combined unique active (CUA) lesions (registered from week 4 to 24)
时间窗: Week 24
次要结局
- Mean number of CUA(at 4, 8, 12, 16, 20 and 24 weeks)
- Mean number of hypointense T1 lesions(at 24 weeks)
- New Gd+ lesions(at 4, 8, 12, 16, 20 and 24 weeks)
- New/enlarging T2 lesions(at 4, 8, 12, 16, 20 and 24 weeks)
研究者
相似试验
终止
3 期
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple SclerosisMultiple Sclerosis, Secondary ProgressiveNCT02430532Biogen58
已完成
3 期
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)Relapsing-Remitting Multiple SclerosisNCT00835770Biogen1,736
已完成
1 期
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT00723359Biotest Pharmaceuticals Corporation32
已完成
2 期
Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)Hidradenitis SuppurativaNCT05093855Staidson (Beijing) Biopharmaceuticals Co., Ltd41
已完成
2 期
BG00012 Phase 2 Combination Study in Participants With Multiple SclerosisRelapsing-Remitting Multiple SclerosisMultiple SclerosisNCT01156311Biogen108